Combinatorial Antitumor Effect of Rapamycin and β -Elemene in Follicular Thyroid Cancer Cells

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Zhou, Jun ^a   He, Li Li ^a   Ding, Xiao Fei ^a   Yuan, Qiu Qi ^b   Zhang, Jian Xin ^a   Liu, Shuang Chun ^c   Chen, Guang ^a  

^a TAIZHOU UNIVERSITY   (China)

^b Taizhou Enze Hospital   (China)

^c Taizhou Municipal Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ELEMENE; PROTEIN KINASE B; RAPAMYCIN; BETA-ELEMENE; SESQUITERPENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; IMMUNOBLOTTING; MALE; MOUSE; MTT ASSAY; NONHUMAN; REGULATORY T LYMPHOCYTE; SPLEEN; T LYMPHOCYTE ACTIVATION; TH17 CELL; THYMUS; THYROID FOLLICULAR CARCINOMA; ANIMAL; DRUG EFFECTS; DRUG SCREENING; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; PATHOLOGY; THYROID FOLLICULAR CELL; THYROID NEOPLASMS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; HUMANS; IMMUNOSUPPRESSION; MICE; SESQUITERPENES; SIROLIMUS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; THYROID EPITHELIAL CELLS; THYROID NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84971327171     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/6723807     Document Type: Article

References (27)

1. J. Goldstein, A. B. Patel, J. L. Curry, V. Subbiah, and S. Piha-Paul, "Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: A case report, " BMC Dermatology, vol. 15, article 2, 2015.
2. S.-F. Lin, Y.-Y. Huang, J.-D. Lin, T.-C. Chou, C. Hsueh, and R. J. Wong, "Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy, " PLoS ONE, vol. 7, no. 10, Article ID e46726, 2012.
3. G. I. Manfredi, A. Dicitore, G. Gaudenzi, M. Caraglia, L. Persani, and G. Vitale, "PI3K/Akt/mTOR signaling in medullary thyroid cancer: A promising molecular target for cancer therapy, " Endocrine, vol. 48, no. 2, pp. 363-370, 2015.
4. C. Papewalis, M. Wuttke, S. Schinner et al., "Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer, " Hormone and Metabolic Research, vol. 41, no. 10, pp. 752-756, 2009.
5. E. C. L. de Souza, A. C. F. Ferreira, and D. P. de Carvalho, "The mTOR protein as a target in thyroid cancer, " Expert Opinion on Therapeutic Targets, vol. 15, no. 9, pp. 1099-1112, 2011.
6. M. Laplante and D. M. Sabatini, "mTOR signaling in growth control and disease, " Cell, vol. 149, no. 2, pp. 274-293, 2012.
7. P. Xia and X. Y. Xu, "PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application, " American Journal of Cancer Research, vol. 5, no. 5, pp. 1602-1609, 2015.
8. X. Wan and L. J. Helman, "The biology behindmTOR inhibition in sarcoma, " Oncologist, vol. 12, no. 8, pp. 1007-1018, 2007.
9. Y.-Y. Zhou, H.-X. Liu, N. Jiang et al., "Elemene, the essential oil of Curcuma wenyujin, inhibits osteogenic differentiation in ankylosing spondylitis, " Joint Bone Spine, vol. 82, no. 2, pp. 100-103, 2015.
10. Q. Q. Li, G. Wang, H. Liang et al., " Elemene promotes cisplatin-induced cell death in human bladder cancer and other carcinomas, " Anticancer Research, vol. 33, no. 4, pp. 1421-1428, 2013.
11. Q. Q. Li, R. X. Lee, H. Liang, and Y. Zhong, "Anticancer activity of elemene and its synthetic analogs in human malignant brain tumor cells, " Anticancer Research, vol. 33, no. 1, pp. 65-76, 2013.
12. Q. Q. Li, R. X. Lee, H. Liang et al., " Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK, " International Journal of Oncology, vol. 43, no. 3, pp. 721-728, 2013.
13. Z. Hu, H. Wu, Y. Li et al., " Elemene inhibits the proliferation of esophageal squamous cell carcinoma by regulating long noncoding RNA-mediated inhibition of hTERT expression, " Anti-Cancer Drugs, vol. 26, no. 5, pp. 531-539, 2014.
14. X. Wan, B. Harkavy, N. Shen, P. Grohar, and L. J. Helman, "Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism, " Oncogene, vol. 26, no. 13, pp. 1932-1940, 2007.
15. Y. Shi, H. Yan, P. Frost, J. Gera, and A. Lichtenstein, "Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade, " Molecular Cancer Therapeutics, vol. 4, no. 10, pp. 1533-1540, 2005.
16. X.-G. Chen, F. Liu, X.-F. Song et al., "Rapamycin regulates Akt and ERK phosphorylation throughmTORC1 andmTORC2 signaling pathways, "Molecular Carcinogenesis, vol. 49, no. 6, pp. 603-610, 2010.
17. M. Gupta, S. M. Ansell, A. J. Novak, S. Kumar, S. H. Kaufmann, and T. E. Witzig, "Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large Bcell lymphoma by inhibiting Akt signaling through mTORC2, " Blood, vol. 114, no. 14, pp. 2926-2935, 2009.
18. W. Mi, Q. Ye, S. Liu, and Q.-B. She, "AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis, " Oncotarget, vol. 6, no. 16, pp. 13962-13977, 2015.
19. Y. H. Zhan, J. Liu, X. J. Qu et al., " Elemene induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of mAPK/ERK and PI3K/Akt/mtor signalling pathways, " Asian Pacific Journal of Cancer Prevention, vol. 13, no. 6, pp. 2739-2744, 2012.
20. S. A. Patel, M. A. Dave, S. A. Bliss et al., "Treg/Th17 polarization by distinct subsets of breast cancer cells is dictated by the interaction with mesenchymal stem cells, " Journal of Cancer Stem Cell Research, vol. 2014, no. 2, p. e1003, 2014.
21. H. Wu, K. Wang, G. Li et al., "Effects of transcutaneous acupoint electrical stimulation on the imbalance of Th1, T2, T17 and Treg cells following thoracotomy of patients with lung cancer, " Experimental and Therapeutic Medicine, vol. 11, no. 2, pp. 495-502, 2016.
22. L. Islas-Vazquez, H. Prado-Garcia, D. Aguilar-Cazares et al., "LAP TGF subset of CD4+CD25+CD127-treg cells is increased and overexpresses LAP TGF in lung adenocarcinoma patients, " BioMed Research International, vol. 2015, Article ID 430943, 11 pages, 2015.
23. X. Wang, L. Wang, Q. Mo, Y. Dong, G. Wang, and A. Jia, "Changes of Th17/Treg cell and related cytokines in pancreatic cancer patients, " International Journal of Clinical and Experimental Pathology, vol. 8, no. 5, pp. 5702-5708, 2015.
24. H. Kopf, G. M. de la Rosa, O. M. Z. Howard, and X. Chen, "Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells, " International Immunopharmacology, vol. 7, no. 13, pp. 1819-1824, 2007.
25. R. Quek, Q. Wang, J. A. Morgan et al., "CombinationmTORand IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors, " Clinical Cancer Research, vol. 17, no. 4, pp. 871-879, 2011.
26. L. Doherty, D. C. Gigas, S. Kesari et al., "Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas, " Neurology, vol. 67, no. 1, pp. 156-158, 2006.
27. A. Awada, F. Cardoso, C. Fontaine et al., "The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics, " European Journal of Cancer, vol. 44, no. 1, pp. 84-91, 2008.